Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24642673 | 0.76 | KDM4E (0.36) | KDM4EKMT2AMEN1 | |
| SCHEMBL1421235 | 0.72 | — | — | |
| SCHEMBL2284491 | 0.71 | KDM4E (0.33) | KDM4EKMT2AMEN1 | |
| SCHEMBL1145180 | 0.71 | KDM4E (0.46) | KDM4EALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL13037671 | 0.71 | KDM4E (0.56) | KDM4EALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL25128594 | 0.70 | EGLN1 (0.35) | KDM4E | |
| SCHEMBL3673998 | 0.69 | KDM4E (0.54) | KDM4EALDH1A1L3MBTL1GAALMNA | |
| SCHEMBL22055533 | 0.69 | MEN1 (0.36) | KDM4EKMT2AMEN1 | |
| SCHEMBL2410168 | 0.69 | — | — | |
| SCHEMBL3778779 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018112843-A1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | claimed |
| WO-2008110891-A2 | NEW HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED, (IN) | 2008-09-18 | — | — | WO | claimed |
| CN-111471021-B | Substituted diamino carboxamides and diamino carbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023226920-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO.,LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| EP-4251613-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-115768775-A | IDH mutant inhibitor and application thereof | 微境生物医药科技(上海)有限公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2022253252-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022111621-A1 | AMINOHETEROARYL KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-02 | — | — | WO | disclosed |
| EP-3986889-A1 | FUNGICIDAL OXADIAZOLES | Bayer Aktiengesellschaft (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-11266147-B2 | Fungicidal oxadiazoles | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-08 | — | — | US | disclosed |
| CN-113845528-A | IDH mutant inhibitor and application thereof | 微境生物医药科技(上海)有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20040209889-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME CORP. | 2004-10-21 | — | — | US | disclosed |
| EP-1379520-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK SHARP & DOHME LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-5304647-A | Addition of an organolithium reagent; dehydrogenation of addition product; two-phase conditions prevents hydrolysis | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1994-04-19 | — | — | US | disclosed |
| US-4963676-A | INTERMEDIATES FOR NOVEL UNFUSED HETEROBICYCLIC COMPOUNDS WITH BIOLOGICAL ACTIVITY; ANTICANCER AGENTS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4929726-A | ANTICARCINOGENIC AGENTS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1990-05-29 | — | — | US | disclosed |
| WO-1989007599-A2 | NOVEL DIAZINES AND THEIR METHOD OF PREPARATION | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209889-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | GRIN1, GRIN2B, GRIN2A | KDM4E 2709/4885ALDH1A1 1273/4885L3MBTL1 3606/4885 |
| US-11266147-B2 | Fungicidal oxadiazoles | CYP51A1, AADAC, CYP4X1 | KDM4E 1329/4885ALDH1A1 234/4885L3MBTL1 1617/4885 |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | GRIN1, GRIN2B, GRIN2A | KDM4E 2372/4885ALDH1A1 1306/4885L3MBTL1 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.